By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Everist Genomics today said that it has received the US Clinical Laboratory Improvement Amendment certification required for it to launch its OncoDefender-CRC assay.

The Ann Arbor, Mich.-based firm plans to officially launch the test, which is a gene-based assay used in stage I and II colon cancer and stage I rectal cancer patients to assess the risk of recurrence following surgery, later this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.